Monika FIDA 医师
医学博士
其他作者: Alesja Palaj, Ina Sotiri, Lejdis Zeneli, Oljeda Kaçani
Autologous micrografting technology for androgenetic alopecia: present and future (educational grant from REGENERA ACTIVA SL)
Objectives: Participants will understand the biological principles and clinical applications of autologous micrografting technology in androgenetic alopecia, including its regenerative mechanisms, patient selection criteria, treatment protocol, current clinical evidence, and future perspectives in hair restoration.
Introduction: Androgenetic alopecia is the most common cause of progressive hair loss, characterized by follicular miniaturization and altered hair cycling. Autologous micrografting technology (AMT) is a regenerative approach based on the mechanical disaggregation of scalp tissue to obtain a suspension enriched with hair follicle stem cells, growth factors, cytokines, extracellular vesicles, and exosomes. Recent advances have improved cell viability and biological activity, expanding the therapeutic potential of AMT in hair restoration.
Materials / method: This presentation reviews the principles, protocol, and scientific evidence supporting AMT in AGA. Tissue samples harvested from the mastoid-occipital scalp are mechanically processed to generate injectable micrografts without enzymatic or chemical manipulation. Clinical indications, patient selection, procedural steps, and outcomes from preclinical and clinical studies evaluating follicular stem cells, extracellular vesicles, exosomes, and hair density changes are discussed.
Results: Preclinical studies demonstrate that AMT suspensions contain viable hair follicle-derived stem cells, regenerative cells, extracellular matrix components, and nanovesicles. Clinical studies have reported significant increases in hair density, with gains of approximately 28–30 hairs/cm² at one year following treatment. High patient and physician satisfaction rates, minimal invasiveness, favorable safety profiles, and the convenience of a single-session point-of-care procedure support the clinical utility of AMT for selected AGA patients.
Conclusion: Autologous micrografting technology represents a promising regenerative strategy for androgenetic alopecia. By delivering stem cells, growth factors, cytokines, and exosomes directly to affected scalp areas, AMT may promote follicular regeneration, angiogenesis, and prolongation of the anagen phase. Growing clinical evidence supports its efficacy and safety, while ongoing research into exosome biology and mechanobiology may further expand its role in personalized hair restoration therapies.